Compare NNVC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | ZLAB |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 2.4B |
| IPO Year | 2008 | 2017 |
| Metric | NNVC | ZLAB |
|---|---|---|
| Price | $1.75 | $17.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | ★ 971.2K | 654.4K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.00 | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $0.85 | $15.96 |
| 52 Week High | $2.23 | $44.34 |
| Indicator | NNVC | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 36.14 |
| Support Level | $1.26 | $16.88 |
| Resistance Level | $1.87 | $19.64 |
| Average True Range (ATR) | 0.18 | 0.82 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 64.94 | 1.61 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.